Drug mean dosage and therapeutic standards for non-pharmacological treatments were considered and summarized, even if not statistically analyzed.
Variables as motive of therapy, daily dosage of the therapy, days of therapy, half-life of systems on the first three days, global half-life of systems, type of anticoagulation, daily mean dosage of citrate-calcium, number of daily changes in these dosages and complications are analysed.
Midazolam mean dosage was significantly higher in the remifentanil group.
Propofol (mean dosage 107 mg (SD 41) or thiopental (mean dosage 306 mg (SD 98)) was used as anaesthetic.
In 38 pairs, patients were treated with norepinephrine (mean dosage of 0.72 μg/kg/min), and 63 were under dobutamine infusion (mean dosage of 9.4 μg/kg/min).
Mean HOMA-B was significantly higher (84 versus 36; P=0.03) and mean dosage of insulin significantly lower (41.5 versus 69.5 units; P=0.004) in SU responders than in SU non-responders.
Almost twice as many patients receiving rivastigmine (mean dosage 9.4 mg/day; n = 59) showed clinically relevant improvements on the NPI-NH as those treated with placebo after 20 weeks (n = 61) (McKeith et al 2000).
Authors reported a 35% reduction in LDL-C with 20 mg every other day (mean dose 18 mg) compared with 38% reduction with 10 mg every day (mean dosage 12 mg/day).
The mean dosage of adjunctive aripiprazole was 9.9 ± 3.2 mg/day.
The mean dosage of lithium was 960 (SD 280) mg a day.
The mean dosage of midazolam used was slightly higher in those children with inadequate sedation (Table 1).
